MS CANNABIS DRAWS CLOSER

Patients are hopeful that cannabis medicines will be available The evidence
for and against cannabis-based drugs for multiple sclerosis is to be tested
by a government watchdog over the next year, it was confirmed on Monday.

The use of cannabinoids to relieve some of the symptoms of the illness is to
be included in the next "work programme" of the National Institute for
Clinical Effectiveness (NICE).

If the go-ahead is given, it is likely they could be available in 2004.

NICE was set up to appraise new and expensive treatments to see if they work
- - and are worth the money.

Cannabinoids - drugs which are derived from the cannabis plant - are under
test in several clinical trials.

Relief From Pain

Some MS patients already smoke the drug illegally, saying that it relieves
some of the muscle stiffness and tremor which characterise the illness.

If approved as a pharmaceutical drug, it would be taken in capsule form - or
as a spray under the tongue - and would probably be formulated so the
patient did not experience any narcotic sensations.

The MS Society, which represents the interests of patients, welcomed the
move.

A spokesman said: "Provided these treatments are shown to work in clinical
trials, we are in favour of getting these drugs to patients suffering from
these symptoms as quickly as possible."

Other controversial drugs are also to come under consideration from NICE.

Leukaemia Drug

Among these is Glivec, which may yet win approval as a therapy for some
patients a form of leukaemia.

Now NICE will examine whether it could help more patients - including those
with an earlier form of the disease.

A study published on Monday added weight to this theory.

It suggested that early leukaemia patients given the drug did benefit.

Other therapies included in the work programme included Mabthera for
non-Hodgkin's lymphoma, and Clopidogrel for heart patients.

Recent trials have suggested both are effective.

Health Minister Lord Hunt said: "NICE was set up to help ensure that
patients have equal access to treatments which are both clinically and cost
effective wherever they live and that the health service has clear
evidence-based guidance on the most up-to-date ways of treating patients."

A spokesman for GW Pharmaceuticals, one of the firms funding trials of
cannabinoids, said: "This is a significant step along the road towards the
nationwide provision of cannabis-based prescription medicines for NHS
patients."